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The endothelium plays a key role in the development of atherogenesis and its inﬂammatory and proliferative status inﬂuences
the progression of atherosclerosis. The aim of this study is to compare the eﬀects of two beta blockers such as nebivolol and
atenolol on gene expression in human umbilical vein endothelial cells (HUVECs) following an oxidant stimulus. HUVECs were
incubated with nebivolol or atenolol (10micromol/L) for 24hours and oxidative stress was induced by the addition of oxidized
(ox)-LDL. Ox-LDL upregulated adhesion molecules (ICAM-1, ICAM-2, ICAM-3, E-selectin, and P-selectin); proteins linked to
inﬂammation (IL-6 and TNFalpha), thrombotic state (tissue factor, PAI-1 and uPA), hypertension such as endothelin-1 (ET-
1), and vascular remodeling such as metalloproteinases (MMP-2, MMP-9) and protease inhibitor (TIMP-1). The exposure of
HUVECs to nebivolol, but not to atenolol, reduced these genes upregulated by oxidative stress both in terms of protein and RNA
expression. The known antioxidant properties of the third generation beta blocker nebivolol seem to account to the observed
diﬀerences seen when compared to atenolol and support the speciﬁc potential protective role of this beta blocker on the expression
of a number of genes involved in the initiation and progression of atherosclerosis.
Copyright © 2008 Ulisse Garbin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nebivolol, a third-generation beta-blocker endowed with
high selectivity for β1 adrenoceptors [1] and with the
capabilitytoreleasenitricoxide(NO)fromendothelium[2],
has been shown to signiﬁcantly aﬀect the amount of reactive
oxygen species (ROS) released from human endothelial cells
under oxidative stress [3–6]. It seems that this eﬀect is
produced, at least in part, by the inhibition of endothelial
NADPH oxidase [7], a key enzyme in the ROS formation
inside the eucariotic cells [8], and also by the direct ROS
scavenging eﬀect of the drug [3, 4, 6, 9].
The oxidative status of cells of the cardiovascular system
is dependent on the balance between ROS and endogenous
antioxidants and recent studies indicate that increase in ROS
is the intracellular signal and marker of their condition
[10, 11]. Extracellular factors such as hypercholesterolemia
with increased oxidized low-density lipoprotein (ox-LDL),
hyperglycemia with enhanced production of advanced gly-
cation end products, hypertension with high levels of
angiotensin II, endothelins, and cytokines can move the
balance toward the prooxidant state of the cell with a
change of its redox state and enhanced formation of ROS
[10, 11]. The change of redox form of the cell induces the
activation of a series of proteins and intracellular enzymes
(epidermal growth factor receptor, c-Src, p38 mitogen-
activated protein kinase, Ras, Akt/protein kinase B) as well as
transcription factors redox-sensitive (NF-κB, AP-1) and the
consequent induction of genes involved in the endothelial
functions (adhesion molecules, prothrombotic factors) and
in the change of the extracellular matrix that is involved
in the formation and progression of the atherosclerotic
disease.
In view of the previous observation of the nebivolol
noticeable inhibitory activity on ROS formation [3–6], the
aim of the present work is to evaluate the potential eﬀect
of the drug on the redox-sensitive genes involved in the
atherosclerotic plaque formation.2 Mediators of Inﬂammation
2. MATERIALS AND METHODS
2.1. Cellcultureandexperimentaldesign
Human umbilical vein endothelial cells (HUVECs) were
obtained according to the method of Jaﬀe et al. [12]
and used at used from passage 2 to 4. The cells were
grown in 75cm2 culture ﬂasks (Falcon, Becton Dickin-
son, Lincoln Park, NJ, USA) ﬁlled with 10mL of M-
199 (Sigma-Aldrich, St. Louis, Mo, USA) containing 10%
fetal calf serum (Seromed, Berlin, Germany), 2mM glu-
tamine (Seromed, Berlin, Germany), 30μgml −1 endothelial
cell growth supplement (Sigma-Aldrich, St. Louis, Mo,
USA), 100μgml −1 heparin (Sigma-Aldrich, St. Louis, Mo,
USA), 100UmL−1 penicillin-streptomycin (Sigma-Aldrich,
St. Louis, Mo, USA), 100μgmL −1 streptomycin (Sigma-
Aldrich, St. Louis, Mo, USA), and 2.5μgmL −1 amphotericin
(Sigma-Aldrich, St. Louis, Mo, USA). The ﬂasks were
incubated at 37◦C, 100% humidity, and 5% of CO2.T h e
medium was refreshed every 2days. At the beginning of
each experiment, the cells were harvested by trypsinization,
using 0.05% trypsin (Sigma-Aldrich, St. Louis, Mo, USA)
and 0.537mM ethylenediamine tetraacetic acid (EDTA) in
phosphate buﬀered saline without calcium and magnesium
(Seromed, Berlin, Germany). The trypsin was inactivated by
dilution, and the cells were washed and counted. Cells were
plated at a concentration of 40000 cellscm2−1 on a multiwell
plate (9.6cm2 well−1) (Falcon, Becton Dickinson, Lincoln
Park, NJ, USA), have grown for 2days, and then used for the
incubations.
HUVECs were harvested and characterized as to acety-
lated LDL binding and factor VIII expression, according
to established and previously described techniques [13].
To assess cell survival, hexosaminidase, a stable cytosolic
enzyme released by cells when they undergo lysis, was
measured according to the method of Landegren [14].
Dl-nebivolol (Berlin Chemie, Menarini Group, Firenze,
Italy) and atenolol (Sigma-Aldrich, St. Louis, Mo, USA)
were dissolved in ethanol and then diluted at the ﬁnal
concentration in culture medium M199. Identical dilutions
of the solvent were prepared and used as control. Since
nebivololwaspreviouslyshowntoreduceinaconcentration-
dependent manner, the intracellular increase of ROS, and
superoxide and to reduce them by 50% at 10μM[ 3], this
concentrationwaschosenthroughoutthestudyandthesame
time of exposure (24hours at 37◦C) was used.
2.2. LDLisolationandoxidation
Whole blood, obtained by venipuncture from healthy volun-
teers (with informed consent) after 12hours of fasting, was
collected into vacutainer tubes (Becton Dickinson, Meylan,
France) containing EDTA (1mgmL−1) ,a n dp r o c e s s e df o r
LDL separation in 1day by sequential ﬂotation in NaBr
solution containing 1mgmL−1 EDTA [15]. Cu2+ modiﬁed
L D L( 1 . 7 m gp r o t e i nm L −1) was prepared by exposure of
LDL to 5μMC u S O 4 for 18hours at 37◦C, and the extent
of LDL oxidation was determined by thiobarbituric acid-
reactive substances, as previously described [16]. Protein
was measured by the Pierce BCA protein assay reagent [13].
Oxidative stress in endothelial cells was induced by the
addition of ox-LDL at the concentration of 50μgp r o t e i n
mL−1 as previously reported [16].
2.3. Macroarray
Gene activation has been evaluated by cDNA array tech-
nology [17] in prepared membranes (SuperArray Bioscience
Corporation) with chemiluminescence detection.
The expression of the following genes have been studied.
Adhesionmolecules
C D H 5 ,I C A M 1 ,I C A M 2 ,I C A M 3 ,I T G A 5 ,I T G A V ,I T G B 1 ,
ITGB3, OCLN (Occludin), PECAM1 (CD31), SELE (E-
selectin), SELL (L-selectin), SELPLG (P-selectin), VCAM1.
Proteinslinkedtoinﬂammation
CCL2 (MCP-1), CCL5 (RANTES), CCL20 (exodus-1), CSF2
(GM-CSF), CSF3 (G-CSF), CX3CL1, IFNB1, IL1B, IL3, IL6,
IL7, IL8, IL11, IL14, IL15, TNF.
Proteinslinkedtoantithromboticorthromboticstate
A N X A 5( a n n e x i nV ) ,C P B 2( T A F I ) ,F 3( t i s s u ef a c t o r ) ,
PLAT (tPA), PLAU (u-PA), SERPINE1 (PAI-1), TFPI, TFPI2,
THBD (thrombomodulin), VWF.
Metalloproteinases
MMP1 (collagenase-1), MMP2 (gelatinase A), MMP3





EDN1 (ET-1), EDN2 (ET-2), EDN3 (ET-3), EDNRA (ETA),
EDNRB (ETB).
2.4. Proteinmeasurement
Proteins related to the genes involved in the oxidative stress
have been measured in the medium by assay kits based
on ELISA system in solid phase. For quantiﬁcation, the
following kits have been used for ICAM-1, E-selectin, P-
selectin, IL6, TNF-alpha, MMP-2, MMP-9, TIMP-1, and ET-
1 R&D Systems kits (USA); for ICAM-2 and ICAM-3 Bender
MedSystemskits(Wien,Austria);fortissuefactor,u-PA,PAI-
1 American Diagnostica kits (Pfungstadt, Germany).
2.5. Statisticalanalysis
Results are expressed as means ± SD. Statistical analysis was
performed by analysis of variance followed by Tukey’s testUlisse Garbin et al. 3
Table 1: Eﬀect of nebivolol and atenolol on protein expression of adhesion molecules (ICAM-1, ICAM-2, ICAM-3, E-selectin, P-selectin),
proteins linked to inﬂammation (IL-6, TNFalpha), and thrombotic state (tissue factor, uPA, PAI-1), endothelin-1 (ET-1), metalloproteinases
(MMP-2, MMP-9), and protease inhibitor (TIMP-1) induced by oxidative stress in endothelial cells.
oxLDL Nebivolol Nebivolol+oxLDL Atenolol Atenolol+oxLDL
ICAM-1 (%) 175 +19∗ 98 ±11 126 ±17∗† 99 ±12 162 ±21∗
ICAM-2 (%) 197 ±28∗ 95 ±13 123 ±25∗† 98 ±15 191 ±32∗
ICAM-3 (%) 152 ±26∗ 103 ±16 113 ±18∗† 101 ±16 140 ±24∗
E-selectin (%) 183+25∗ 99 ±16 137 ±21∗† 102 ±15 180 ±23∗
P-selectin (%) 245 ±29∗ 102 ±14 179 ±25∗† 99 ±17 236 ±27∗
IL-6 (%) 335 ±39∗ 98 ±16 180 ±21∗† 97 ±16 341 ±37∗
TNFalpha (%) 378 ±46∗ 100 ±15 221 ±31∗† 102 ±14 366 ±48∗
TF (%) 196 ±27∗ 99 ±15 149 ±21∗† 100 ±17 199 ±30∗
u-PA (%) 189 ±24∗ 99 ±16 140 ±25∗† 98 ±12 191 ±27∗
PAI-1 (%) 203 ±30∗ 101 ±15 179 ±25∗† 98 ±15 236 ±27∗
ET-1 (%) 275 ±32∗ 97 ±13 163 ±25∗† 101 ±16 266 ±35∗
MMP2 (%) 287 ±36∗ 99 ±13 161 ±21∗† 100 ±15 296 ±39∗
MMP9 (%) 216 ±29∗ 101 ±11 161 ±19∗† 99 ±13 205 ±27∗
TIMP-1 (%) 737 ±96∗ 102 ±13 459 ±65∗† 99 ±12 721 ±88∗
Legend: data are means ±SD and are expressed as % increase versus control;
∗P<. 001 versus control; †P<. 01 versus oxLDL.
post-hoc analysis. All data were analyzed using the “SPSS 11”
program for Macintosh.
3. RESULTS
Among the genes examined by macroarray, only ICAM-1,
ICAM-2, ICAM-3, E-selectin, P ligand-selectin, IL-6, TNF-
alpha, tissue Factor, PAI-1, uPA, TIMP-1, MMP-2, MMP-
9, and ET-1 were upregulated by the exposure of HUVECs
to ox-LDL and, therefore, the protein related to them was
measured. The expression of the adhesion molecules studied
(ICAM-1, ICAM-2, ICAM-3, E-selectin, P ligand-selectin)
signiﬁcantly increased (P<. 001) after the exposure of
H U V E C st oo x - L D La sb o t hR N A( Figure 1)a n dp r o t e i n
levels (Table 1). Nebivolol, but not atenolol, was able to
signiﬁcantly reduce this increase by 41.7 ± 4.8% for RNA
(Figure 1), by 28 ± 3.1% for protein (Table 1)o fI C A M - 1
(P<. 01), by 37.9±4.6% for RNA (Figure 1), by 37.6±3.9%
for protein (Table 1)o fI C A M - 2( P<. 01), by 30.0±3.5% for
RNA (Figure 1), and by 25.7 ± 3.1% for protein of ICAM-3
(P<. 01), respectively. Similarly, only nebivolol signiﬁcantly
reduced selectins expression induced by ox-LDL by 30.4 ±
3.7% and 36.1±4.1% for RNA (Figure 1)a n db y2 5 .1±2.7%
and 26.9 ± 3.4% for protein (Table 1), respectively for E-
selectin and P-selectin (P<. 01).
The expression of both RNA (Figure 2)a n d p r o t e i n
(Table 1) of molecules involved in inﬂammation such as
IL-6 and TNF-alpha was signiﬁcantly increased by ox-LDL
exposure (P<. 001). Nebivolol, but not atenolol, was able
to reduce this increase by 48.4 ± 5.6% for RNA (Figure 1),
by 46.3 ± 4.9% for protein (Table 1)o fI L - 6( P<. 01), by
53.7 ± 5.9% for RNA (Figure 1), and by 41.3 ± 3.9% for
protein (Table 1) of TNF-alpha (P<. 01), respectively.
As shown in Figure 2 and Table 1, the expression of




















































Figure 1: Eﬀect of nebivolol and atenolol on RNA expression
of adhesion molecules (ICAM-1, ICAM-2, ICAM-3, E-selectin,
and P-selectin) induced by oxidative stress in human umbilical
vein endothelial cells (HUVECs). HUVECs were incubated with
nebivolol or atenolol (10μM) for 24hours at 37◦C; oxidative stress
was induced by the addition of oxidized (ox)LDL (50μgp r o t e i n
mL−1). ∗P<. 001 versus control; †P<. 01 versus ox-LDL. AU =
arbitrary units. Data are expressed as means ± SD of 6 diﬀerent
experiments.
processsuchastissueFactor,PAI-1anduPAwassigniﬁcantly
increased (P<. 001) by the exposure of HUVECs to ox-
LDL. Nebivolol, but not atenolol, at least in part reduced
these values as follows: tissue factor −42.1 ± 4.8% for RNA,
−30 ± 2.7% for protein (P<. 01), PAI-1 −41.7 ± 4.6% and
−27.1 ± 2.5% for protein (P<. 01), uPA −35.6 ± 4.1% for
RNA, and −25.9 ±2.8% for protein (P<. 01).
Overexpression of metalloproteinases (MMP-2 and
MMP-9) and protease inhibitor TIMP-1 was signiﬁcantly
induced by ox-LDL in HUVECs both as RNA (Figure 3)a n d





















































Figure 2: Eﬀect of nebivolol and atenolol on RNA expression
of proteins linked to inﬂammation (IL-6 and TNFalpha) and to
thrombotic state (tissue factor, PAI-1, and uPA) induced by oxida-
tive stress in human umbilical vein endothelial cells (HUVECs).
HUVECs were incubated with nebivolol or atenolol (10μM) for
24hours at 37◦C; oxidative stress was induced by the addition of
oxidized (ox)LDL (50μgp r o t e i nm L −1). ∗P<. 001 versus control;
†P<. 01 versus ox-LDL. AU = arbitrary units. Data are expressed as
means ±SD of 6 diﬀerent experiments.
atenolol, was able to reduce this increase by 56.7 ± 6.3%
for RNA (Figure 3), by 43.9 ± 4.1% for protein (Table 1)o f
MMP-2 (P<. 01), by 29.6 ± 3.5% for RNA (Figure 3), by
25.5 ± 2.9% for protein (Table 1) of MMP-9, by 46.6 ± 5.4%
for RNA (Figure 3), and by 37.7±4.9% (P<. 05) for protein
(Table 1)o fT I M P - 1( P<. 01), respectively. Finally also the
expression of ET-1 was signiﬁcantly increased (P<. 001)
after the exposure of HUVECs to ox-LDL as both RNA
(Figure 3)a n dp r o t e i n( Table 1). Nebivolol, but not atenolol,
w a sa b l et or e d u c et h i si n c r e a s eb y3 4 .5 ± 3.9% for RNA




and atenolol on gene expression in response to oxidative
stress induced by ox-LDL in cultured HUVECs. Ox-LDL is
a proatherogenic lipoprotein that has been identiﬁed as a
potent stimulus for vascular ROS and has been suggested
to modulate gene expression of vascular cells [18]b ya
speciﬁc binding to the receptor LOX-1 [16]. The ﬁrst
result of this study is that ox-LDL signiﬁcantly increased
the expression of some genes involved in the formation
and progression of atherosclerotic plaque [19]. Our results
are in accordance with recent ﬁndings showing that ox-
LDL upregulates cell-cell interaction, inﬂammation, growth,
apoptosis, and hemostasis genes in smooth muscle cells and
macrophages [20, 21].
In this study, we also found that nebivolol decreased
ICAMs, P- and E-selectin at the mRNA, and protein level
expression in HUVECs exposed to oxidative stress, whereas
atenolol was ineﬀective. Our ﬁndings, even in diﬀerent













































Figure 3: Eﬀect of nebivolol and atenolol on RNA expression
of endothelin-1 (ET-1), metalloproteinases (MMP-2, MMP-9)
and protease inhibitor (TIMP-1) induced by oxidative stress in
human umbilical vein endothelial cells (HUVECs). HUVECs were
incubated with nebivolol or atenolol (10 μM) for 24 hours at 37◦C;
oxidative stress was induced by the addition of oxidized (ox)LDL
(50μgp r o t e i nm L −1). ∗P<. 001 versus control; †P<. 01 versus ox-
LDL. AU = arbitrary units. Data are expressed as means ± SD of 6
diﬀerent experiments.
showing that nebivolol reduced adhesion molecules genes
expression in human coronary endothelial and vascular
smooth muscle cells [22]. Adhesion molecules mediate
the ﬁrst step in leukocyte extravasation which stands at
the very beginning of the cascade of events leading to
plaque formation [19]. P- and E-selectins, that are expressed
only on activated endothelium, have been demonstrated
to play an important role in both early and advanced
stages of atherosclerotic lesion development [23]; absence
of P-selectin, in fact, has been found to delay fatty streak
formation in mice [24]. Several studies have reported
increased plasma levels of E-selectin and ICAM-1 in patients
with hypertension, diabetes, and hypercholesterolemia [25–
27, 34]; moreover in patients at cardiovascular risk, plasma
concentration of ICAM-1 can predict adverse outcome [28].
Another important result of this study is the ability of
nebivolol, but not of atenolol, to signiﬁcantly reduce the
oxidative stress-induced TNF-alpha, IL-6, and ET-1 gene
expression in HUVECs. This ﬁnding is in agreement with
a previous study showing that nebivolol can reduce ET-1
secretioninhumancoronarysmoothmuscleandendothelial
cells [29]. Inﬂammation plays a key role in mediating
all stages of atherosclerosis which is considered a chronic
inﬂammatory disease [19]. Proinﬂammatory cytokines as
TNF-alpha and IL-6 have both been shown to induce
structuralaswellasfunctionalalterationsinendothelialcells.
These cytokines are known to stimulate the production of
endothelin and ROS, reduce acetylcholine-induced vasodi-
latation,andnegativelyaﬀectthemRNAofendothelialnitric
oxide synthase [30].
In our study, nebivolol also signiﬁcantly reduced the
increased gene expression of tissue factor, one of the
pivotal thrombogenic stimuli, PAI-1 and uPA induced by
ox-LDL. Atenolol on the contrary was ineﬀective. In thisUlisse Garbin et al. 5
context, it has been recently demonstrated in hypertensive
patients that treatment with nebivolol was associated with a
favorable modiﬁcation of hemostatic and ﬁbrinolytic status
in addition to its antihypertensive eﬀects [31]. The plas-
minogen activator (PA) system plays a key role in vascular
homeostasis and constitutes a critical response mechanism
to cardiovascular injury. It includes the proteolytic activators
as u-PA, plasminogen and its degradation product, plasmin,
together with the major inhibitors of this system, PAI-1and
PAI-2.
An extensive network of additional proteases, inhibitors,
receptors, and modulators is directly associated and inﬂu-
enced by the PA system, the largest group being the
MMPs and their respective inhibitors TIMPs [32]. MMPs
play an important role in atherosclerosis by degrading the
extracellular matrix and contributing to weakening of the
vascular wall. Moreover, increased expression of TIMP-1 was
demonstrated in atherosclerotic plaques of cholesterol-fed
rabbit [33].
Our results showing that ox-LDL increased the expres-
sion of MMPs in HUVECs conﬁrm other experimental
evidences demonstrating that oxidative stress directly acti-
vate MMPs posttranslationally [35]. Present ﬁndings show
for the ﬁrst time that nebivolol signiﬁcantly reduced gene
expression of MMPs and TIMPs in HUVECs, whereas
treatment with atenolol had no eﬀect. This result is likely
due to the peculiar antioxidant activity of nebivolol and
seemstobeindependenttoitsbeta-blockeractivitysincealso
propranolol was ineﬀective in reducing MMPs expression in
experimental atherosclerosis [36].
In conclusion the results of our study demonstrated
that in cultured endothelial cells exposed to oxidative stress
nebivolol can reduce the expression of a number of genes
involved in the initiation and progression of atherosclerosis.
We and others have already demonstrated that nebivolol
decreased ROS concentration by aﬀecting the signalling
pathways leading to NADPH oxidase activation in endothe-
lial cells [3], in experimental hyperlipidemia [37, 38] and in
angiotensin II-treated rats [7]. We can, therefore, speculate
that our results depend on the ability of nebivolol to reduce
intracellular ROS concentration and hence to restore redox
state in endothelial cells.
Our ﬁndings suggest that nebivolol, in addition to
its antihypertensive eﬀect, can be useful in preventing
atherosclerotic complications related to oxidative stress.
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